#### **BVF PARTNERS L P/IL**

Form 4

December 19, 2018

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

0.5

January 31, Expires: 2005

**OMB APPROVAL** 

Estimated average

burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **BVF PARTNERS L P/IL** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

6. Individual or Joint/Group Filing(Check

Symbol

12/14/2018

(Last)

(First) (Middle) XOMA Corp [XOMA]

(Check all applicable)

3. Date of Earliest Transaction (Month/Day/Year)

Director Officer (give title

\_\_ 10% Owner Other (specify

44 MONTGOMERY STREET, 40TH FLOOR

> (Street) 4. If Amendment, Date Original

> > Filed(Month/Day/Year)

Applicable Line)

Form filed by One Reporting Person X\_ Form filed by More than One Reporting

below)

SAN FRANCISCO, CA 94104

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 4. Securities Acquired (A) 5. Amount of 3.

7. Nature of Ownership Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) (D) Code V Amount Price

Common Stock.

\$0.0075 12/17/2018 par value

25,000 A

P

718,541

 $D^{(3)}$ 

per share (1)

Common

Stock.

\$0.0075 par value

per share

(1)

694,961  $D^{(2)}$ 

## Edgar Filing: BVF PARTNERS L P/IL - Form 4

Common			
Stock,			
\$0.0075	123,649	D (4)	
par value	123,049	<u>υ</u>	
per share			
<u>(1)</u>			
Common			
Stock,			Caa
\$0.0075	221 070	I (5)	See footnote
par value	231,878	1 (3)	(5)
per share			<u>(0)</u>
(1)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of stiorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Subscription Rights	\$ 13,000	12/14/2018		X		345.313	11/19/2018	12/14/2018	Series Converti Preferre Stock, \$0 par valu
Series Y Convertible Preferred Stock	(8)	12/14/2018		X	345.313 (6)		(8)	(8)	Stock \$0.0075 value p
Subscription Rights	\$ 13,000	12/14/2018		X		224.813	11/19/2018	12/14/2018	Series Converti Preferre Stock, \$0 par valu
Series Y Convertible Preferred	<u>(8)</u>	12/14/2018		X	224.813 ( <u>6)</u>		<u>(8)</u>	(8)	Commo Stock, \$0.0075

## Edgar Filing: BVF PARTNERS L P/IL - Form 4

Stock							value p share
Series Y Convertible Preferred Stock	<u>(8)</u>	12/18/2018	X	310.646 (7)	(8	<u>(8)</u>	Commo Stock \$0.0075 value p share
Series Y Convertible Preferred Stock	<u>(8)</u>	12/18/2018	X	372 (7)	<u>(8</u>	<u>(8)</u>	Commo Stock, \$0.0075 value p share
Series X Convertible Preferred Stock	<u>(9)</u>				<u>(9</u>	<u>(9)</u>	Commo Stock, \$0.0075 value p share
Series X Convertible Preferred Stock	<u>(9)</u>				<u>(9</u>	<u>(9)</u>	Commo Stock. \$0.0075 value p share
Series X Convertible Preferred Stock	<u>(9)</u>				<u>(9</u>	<u>(9)</u>	Commo Stock. \$0.0075 value p share
Series X Convertible Preferred Stock	<u>(9)</u>				<u>(9</u>	<u>(9)</u>	Commo Stock, \$0.0075 value p share

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
copyround a whole i while / i a ware and	Director	10% Owner	Officer	Other		
BVF PARTNERS L P/IL 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA 94104		X				
BIOTECHNOLOGY VALUE FUND L P 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA 94104				See Explanation of Responses		

Reporting Owners 3

### Edgar Filing: BVF PARTNERS L P/IL - Form 4

BIOTECHNOLOGY VALUE FUND II LP

44 MONTGOMERY STREET

40TH FLOOR

See Explanation of Responses

SAN FRANCISCO, CA 94104

Biotechnology Value Trading Fund OS LP

P.O. BOX 309 UGLAND HOUSE See Explanation of Responses

GRAND CAYMAN, E9 KY1-1104

BVF Partners OS Ltd.

P.O. BOX 309 UGLAND HOUSE See Explanation of Responses

X

GRAND CAYMAN, E9 KY1-1104

**BVF INC/IL** 

44 MONTGOMERY STREET

X

40TH FLOOR

SAN FRANCISCO, CA 94104

LAMPERT MARK N

44 MONTGOMERY STREET

40TH FLOOR

SAN FRANCISCO, CA 94104

# **Signatures**

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President				
**Signature of Reporting Person	Date			
Biotechnology Value Fund, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	12/19/2018			
**Signature of Reporting Person	Date			
Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	12/19/2018			
**Signature of Reporting Person	Date			
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President				
**Signature of Reporting Person	Date			
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	12/19/2018			
**Signature of Reporting Person	Date			
BVF Inc., By: /s/ Mark N. Lampert, President	12/19/2018			
**Signature of Reporting Person	Date			
/s/ Mark N. Lampert	12/19/2018			
**Signature of Reporting Person	Date			

Signatures 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and
- (1) Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of the Common Stock reported herein except to the extent of his or its pecuniary interest therein.
- Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  - Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners
- (4) OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  - Securities held in certain Partners managed accounts (the "Partners Managed Accounts"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the
- (5) investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts.
- (6) Series Y Convertible Preferred Stock acquired by BVF and BVF2 following the exercise of each of its basic subscription privilege in connection with the Issuer's subscription rights offering (the "Offering").
- (7) Series Y Convertible Preferred Stock acquired by BVF and BVF2 pursuant to the terms and conditions of a backstop commitment made by the Reporting Persons in connection with the Offering.
  - The Series Y Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 19.99% of the shares of Common Stock outstanding immediately after giving
- (8) effect to such exercise. The Series Y Convertible Preferred Stock does not have an expiration date. The initial conversion price is \$13.00 and is subject to certain adjustments pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series Y Convertible Preferred Stock.
  - The Series X Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 19.99% of the shares of Common Stock outstanding immediately after giving
- (9) effect to such exercise. The Series X Convertible Preferred Stock does not have an expiration date. The initial conversion price is \$4.03 and is subject to certain adjustments pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.